LexaGene Blog Diagnostics Diary

Overuse of antimicrobial agents in veterinary medicine contributes to the spread of resistance genes which undermine our ability to prevent or treat infectious disease.

Veterinary Antimicrobial Stewardship programs are critical to not only improve patient outcomes, but support global action against antimicrobial resistance.

Pandemic containment in the United States has proved ineffective due to a lack of preparation and deployment of modern pathogen-detection technologies. Improved point-of-care molecular diagnostics will save lives when the next pandemic emerges.

Antimicrobial-resistant pathogens cause one in five infections in OECD and EU28 nations and could kill up to 10 million people per year by 2050. What drives antimicrobial resistance and what impacts can we expect?

qPCR is used to quickly identify pathogens and antimicrobial resistance markers in a small sample and is indispensable for modern point-of-care molecular diagnostics.

Dr. Jack Regan discusses scaling MiQLab production and preparing for SNN Network’s Summer Virtual Event, the premier event in MicroCap Finance, with Stock News Now’s CEO Robert Kraft.

The company will be approaching Government and showing the effectiveness and speed of their MiQLab in detecting plague.

Dr. Jack Regan, LexaGene’s CEO gives his perspective on fighting COVID-19 with better diagnostics and automated PCR testing.

Live from the Floor with Dr. Jack Regan, Founder and CEO.

Dr. Regan sat down with Steve Darling from Proactive to explain the importance of this milestone for MiQLab customers in veterinary diagnostics, pharmaceutical production, and bioprocessing.

Dr. Jack Regan discusses scaling MiQLab production and preparing for SNN Network’s Summer Virtual Event.

Check out Proactive Investors’ coverage of LexaGene’s contract with Alpine Veterinary Hospital – and Dr Regan’s upcoming conference appearances.
« Previous PageNext Page »